Arginne deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment
AssigneePolaris Group
InventorsRobert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
Claims41
A therapeutic composition comprising an isolated arginine deiminase, or a fragment thereof having ADI activity, and a pharmaceutically-acceptable carrier, wherein the isolated arginine deiminase has reduced cross-reactivity with patient anti-ADI-PEG 20 antibodies.
The therapeutic composition of any one of the preceding claims wherein the isolated arginine deiminase has been modified to remove at least one pegylation site.
The therapeutic composition of any one of the preceding claims wherein at least one lysine residue has been modified by an amino acid substitution.
The therapeutic composition of any one of the preceding claims wherein the arginine deiminase is covalently bonded via a linker to a PEG molecule.
29-56. (canceled)
(canceled)
Dependencies are inferred from the claim text.